A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata

The registered record

Accession number

NCT07023302

Lead sponsor

AbbVie (industry)

Registered condition naming hair loss

Alopecia Areata

Official title

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Alopecia Areata and at Least 25% Scalp Hair Loss

Interventions

• DrugUpadacitinib
• DrugUpadacitinib Placebo

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type

interventional

Phase

Phase 3

Allocation

randomized

Masking

double

Primary purpose

treatment

Enrolment

125 participants (actual)

Sites

15 locations in Japan

What it measures

1. Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 10

   Time frame: Week 24

2. Number of Participants with Adverse Events (AEs)

   Time frame: Up to approximately 108 weeks

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex

all

Age

12 Years to 63 Years

Healthy volunteers

not accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start

19 June 2025 (actual)

Primary completion

February 2029 (estimated)

Study completion

February 2029 (estimated)

First posted

16 June 2025 (actual)

Last update posted

30 July 2026 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: a primary completion registered as 2029-02 is a month, and rendering it as 1 February 2029 would invent a day the sponsor did not register.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Alopecia Areata: Types, Treatment, and OutlookJAK Inhibitors for Alopecia Areata: Baricitinib, Ritlecitinib and Deuruxolitinib, Trial by Trial

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT07023302 on ClinicalTrials.gov · All 157 trials in the pipeline